

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 758 901 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

19.12.2001 Bulletin 2001/51

(51) Int Cl.7: **A61K 38/20**

(86) International application number:
PCT/US95/02452

(21) Application number: **95911976.9**

(87) International publication number:
WO 95/28951 (02.11.1995 Gazette 1995/47)

(22) Date of filing: **28.02.1995**

(54) FORMULATIONS FOR IL-11

INTERLEUKIN-11 PRÄPARAT

PREPARATIONS CONTENANT IL-11

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(74) Representative: **VOSSIUS & PARTNER**
Postfach 86 07 67
81634 München (DE)

(30) Priority: **21.04.1994 US 230982**

(56) References cited:
EP-A- 0 158 487 EP-A- 0 578 823
WO-A-94/05318

(43) Date of publication of application:
26.02.1997 Bulletin 1997/09

(73) Proprietor: **GENETICS INSTITUTE, INC.**
Cambridge Massachusetts 02140 (US)

- : "", BIOCHEMICA ET BIOPHYSICA ACTA, 1990,
vol. 1041, no. , pages 178 to 185
- : "", J. OF PROTEIN CHEMISTRY, 1992, , vol. 11,
no. 3, pages 321 to 331
- : "", PROGRESS IN GROWTH FACTOR
RESEARCH, 1990, , vol. 4, no. , pages 157 to 170
- : "", PROTEIN SEQUENCES & DATA ANALYSIS,
1992, , vol. 5, no. , pages 57 to 64

(72) Inventor: **WARNE, Nicholas W.**
Methuen, MA 01844 (US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to novel formulations comprising IL-11.

[0002] A variety of regulatory molecules, known as cytokines, have been identified including interleukin-11 (IL-11). IL-11 stimulates a variety of hematopoietic and immune functions. The various protein forms of IL-11 and DNA encoding various forms of IL-11 activity are described in Bennett, *et al.*, USPN 5,215,895 (June 1, 1993); McCoy, *et al.*, USPN 5,270,181 (December 14, 1993); and McCoy, *et al.*, USPN 5,292,646 (March 8, 1994), and incorporated herein by reference. Thus, the term "IL-11" includes protein produced by recombinant genetic engineering techniques; purified from cell sources producing the factor naturally or upon induction with other factors; or synthesized by chemical techniques; or a combination of the foregoing.

[0003] To maximize the pharmacological benefit of any protein, it is essential to have finished dosage forms that are stable, easily and reproducibly manufactured, and designed for standard routes of administration. Specifically, it is desirable to have stable, concentrated forms of bulk protein, e.g., IL-11 which, in turn, are suitable for further manufacture of finished dosage forms of protein, which can then be administered e.g., via *sub cutaneous* injection.

[0004] In both bulk protein and finished dosage forms, protein stability can be affected by such factors as ionic strength, pH, temperature, repeated cycles of freeze/thaw and shear forces. Active protein may be lost as a result of physical instabilities, including denaturation and aggregation (both soluble and insoluble aggregate formation), as well as chemical instabilities, including, for example, hydrolysis, deamidation, and oxidation, to name just a few. For a general review of stability of protein pharmaceuticals, see, for example, Manning, *et al.*, Pharmaceutical Research 6: 903-918 (1989). In addition, it is desirable to maintain stability in the absence of carrier proteins.

[0005] While it is widely appreciated that these possible protein instabilities can occur, until a protein has been studied it is impossible to predict the particular instability problems that a particular protein may have. Any of these instabilities can potentially result in the formation of a protein or protein by-product or derivative having lowered activity, increased toxicity, and/or increased immunogenicity. Indeed, protein precipitation can lead to thrombosis, non-homogeneity of dosage form and immune reactions. Thus, the safety and efficacy of any pharmaceutical formulation of a protein is directly related to its stability.

[0006] WO-A-94/05318 describes IL-11 preparations containing stabilizers, EP-A-0 158 487 discloses interleukin-2 compositions containing glycine as stabilizer and EP-A 578 823 discloses the use of phosphates as buffers in interleukin preparations.

[0007] Accordingly, there continues to exist a need in the art for methods for improving protein stability during the concentration process as well as providing stability in the absence of other carrier proteins in a concentration sufficiently high for various routes of administration including, e.g., *sub cutaneous* injection, *intra venous* injection.

[0008] One aspect of the present invention provides novel compositions and methods for obtaining concentrated preparations of IL-11, useful as bulk drug product.

[0009] Another aspect of the present invention provides compositions comprising formulations of IL-11 of a concentration, useful for administration in final dosage forms.

[0010] The compositions include IL-11, glycine, and a buffering agent. Preferred glycine concentrations range from 100 mM to 300 mM, with 300 mM most preferred. IL-11 concentration ranges from 0.1 mg/mL to 20.0 mg/mL, the most preferred being 5.0 mg/mL. Suitable buffering agents include histidine and sodium phosphate, ranging in concentration from 5 mM to 40 mM; with 10 mM preferred for sodium phosphate and 20 mM preferred for histidine, with sodium phosphate being the preferred buffering agent.

[0011] The compositions of the present invention may be either frozen, liquid, or lyophilized.

[0012] In developing an appropriate drug dosage formulation, various factors are considered, including the solubility of a particular protein, its stability, and any particular handling requirements associated with the protein. While not all proteins are sensitive to handling, Applicants find that IL-11 is, in fact, sensitive to handling; both soluble aggregate and precipitate formation is observed after the protein has been "handled." Such handling includes, for example, any of the usual normal shear forces associated with shipping to clinical sites and with packaging operations. Also, sometimes protein formulations are pumped through stainless steel or other tubing during manufacture or stressed by the delivery systems which can subject them to shear forces; sometimes it is necessary to subject the protein to a variety of freeze/thaw cycles, thereby also exposing the protein to potential denaturations.

[0013] While some efforts have been undertaken to overcome the stability problem by lyophilizing the protein of interest and shipping the protein in lyophilized form, once the protein has reached its destination it must be reconstituted by either the health care worker or the patient. Proper reconstitution requires that the procedure be done under sterile conditions, that it be done gently, and that an assessment be made regarding the integrity of the reconstituted solution. Because of potential inconveniences associated with the use of lyophilized dosage forms, when possible, liquid dosage forms are more desirable. Development of stable liquid dosage forms of protein pharmaceuticals is a challenge, because generally the liquid form is less stable than the lyophilized form. However, if the stability problems of a liquid dosage form are overcome, the liquid form can be utilized.

[0014] Applicants find that some of the chemical instability of IL-11 is a result of hydrolysis between Asp¹³³ and Pro¹³⁴. Also, deamidation of Asn⁴⁹ to Asp⁴⁹ is detected. In addition, oxidation of Met⁵⁸ is observed. All of these chemical reactions are evidence of IL-11 protein chemical instability. IL-11 is also subject to certain physical instabilities including a dimerization process (which is actually a shift in equilibrium between the monomeric and dimeric forms of IL-11), as well as aggregate formation.

[0015] According to the present invention, the addition of glycine, at an appropriate pH, acts to prevent aggregation of IL-11 and protects IL-11 from the harmful effects of shearing. This in turn increases the ability to handle the protein and provides enhanced shelf-life for IL-11 products. The present invention also provides for IL-11 formulations, containing glycine, which are suitable for *sub cutaneous* injection. The IL-11 concentration ranges from 0.5 to 20.0 mg/mL. The IL-11 formulation can be in either a liquid or a lyophilized dosage form. Moreover, addition of an appropriate buffering agent slows the rate of hydrolysis, deamidation, and oxidation. Buffering is accomplished with a suitable buffer, or any buffering agent as is known to one skilled in the art, which will adequately buffer at neutral pH. Preferred is histidine; most preferred is sodium phosphate.

[0016] The following examples illustrate practice of the invention. These examples are for illustrative purposes only and are not intended in any way to limit the scope of the invention claimed. Example 1 describes the effects of various excipients on the shearing of IL-11. Example 2 relates to concentrating IL-11 solutions. Example 3 describes the thermal stability of IL-11 containing solutions. Example 4 relates to long-term IL-11 stability.

EXAMPLE 1 RESISTANCE TO SHEAR EFFECTS

[0017] To examine the shear protecting effects of various excipients on the shearing of IL-11, IL-11 is added to solutions containing various buffers as set forth in Table I. Specifically, 2 mg/mL rhIL-11, in 20 mM sodium phosphate, 0.15 M NaCl, pH 7.0, is spiked into solutions containing various buffers and the solutions, at 0.1 mg/mL in 1-mL volume, are stirred vigorously at approximately 100 rpm using a triangular reacti-vial for 20 minutes. All samples are prepared in triplicate. Samples are centrifuged and the supernatant examined for protein concentration by Size-Exclusion High-Performance Liquid Chromatography (SEC-HPLC). Table I shows the effects of excipients on the recovery of rhIL-11.

[0018] Percent recovery is determined by examining samples before and after stirring. 100 μ L aliquots are injected onto a TosoHaas TSK2000SW_{XL} HPLC column (cat. #08540) using a buffer of 50 mM MES, 0.5 M NaCl, pH 6.0, at a flow rate of 1 mL/min. Absorbance is monitored at 280 nm. A Waters HPLC system is used (Waters 600 multi-solvent delivery system, Waters 600E system controller, Waters WISP 712 auto-injector, Waters 490E programmable multi-wavelength detector and the Waters Expert HPLC software package). Percent recovery is determined by dividing the absorbance area of the rhIL-11 peak in the stirred sample by the absorbance area of the control sample. The recoveries of the three samples are averaged.

Table I
Excipient Effects on Shearing of rhIL-11

| Base Buffer | Additive ¹ | pH | Percent Recovery |
|------------------------|-------------------------|-----|------------------|
| 50 mM sodium phosphate | 150 mM NaCl | 6.0 | 74 |
| | 1 M NaCl | 6.0 | 65 |
| 10 mM Histidine | 1 M NaCl | 7.5 | 89 |
| | 20 mM CaCl ₂ | 7.5 | 89 |
| | 20 mM MgCl ₂ | 7.5 | 89 |
| | 0.2 M glycine | 7.5 | 97 |
| | 0.5 M NaCl | 7.0 | 71 |
| | 0.2 M ethyl glycine | 7.0 | 98 |
| | 0.2 M BAPA | 7.0 | 77 |
| | 0.2 M GABA | 7.0 | 47 |
| | 0.2 M EACA | 7.0 | 84 |
| | 0.2 M DAVA | 7.0 | 63 |

GABA = γ -amino-n-butyric acid

EACA = ϵ -amino-n-caproic acid

DAVA = δ -amino-n-valeric acid

BAPA = β -amino-n-propionic acid

[0019] The greatest shear-protecting effects are observed with glycine, ethyl glycine, calcium chloride, and ϵ -amino-n-caproic acid.

EXAMPLE 2 CONCENTRATING IL-11 SOLUTIONS

[0020] This example demonstrates the solubilizing effects of glycine. Samples are prepared to examine the effects of concentrating IL-11 solutions. Applicants find that stirred cell concentrating of IL-11, in the absence of glycine, leads to poor recoveries (85-90%) and can lead to increased levels of multimeric IL-11. The apparent molecular weights of these species, as determined using size-exclusion high-performance liquid chromatography, correspond to dimeric and trimeric forms.

[0021] An IL-11 containing solution (500 mL at 0.4 mg/mL) in 20 mM L-histidine, 0.25 M NaCl, pH 7.0, is concentrated to 5 mg/mL (40 mL) using a 100 mL stirred cell at 60 psi. As the volume decreases and the protein concentration increases, during the ultrafiltration step, the flow rate of solution through the YM10 (10 kD molecular weight cutoff) membrane decreases. This decrease in flow rate is due to a deposit of a layer of protein on the surface of the membrane. As the diafiltration step begins, and the glycine containing buffer is introduced (20 mM L-histidine, 0.3 M glycine, pH 7.0), the flow rate increases. This increase in flow rate is indicative of a solubilization of the layer of protein deposited on the membrane surface. Thus, utilizing glycine increases IL-11 recoveries from 85-90% to 98-100%.

EXAMPLE 3 THERMAL STABILITY OF IL-11

[0022] This example demonstrates that the addition of glycine increases the temperature to which IL-11 will remain soluble.

[0023] Thermal denaturation of IL-11 containing solutions is performed using an SLM/Aminco 8000C fluorescence spectrophotometer. As IL-11 denatures in solution, it precipitates. Based on this observation, a fluorescence spectrophotometer is used to monitor right-angle light-scattering by exciting the sample at 320 nm, and monitoring emission also at 320 nm. The emission signal is monitored continuously as the temperature of the cuvette is raised at a rate of 1°C/minute. Temperature is controlled using a Neslab 110C gradient controlled waterbath. The temperature at which 50% of the protein is precipitated is described as the precipitation temperature (T_p).

[0024] Solutions containing various amounts of IL-11 were thermally denatured. As the protein concentration increases, in general the T_p decreases as the precipitation event is protein concentration dependent. Two solutions of IL-11 are examined: PBS (50 mM sodium phosphate, 150 mM NaCl, pH 7.0) and a glycine containing solution of 20 mM L-histidine, 300 mM glycine, pH 7.0. Table II demonstrates that as the protein concentration increases, the T_p decreases dramatically in the PBS solution, but not in the glycine containing solution. The data demonstrates that glycine helps to stabilize IL-11 in solution.

Table II

| Effect of IL-11 Concentration on Precipitation Temperature | | |
|--|---|---|
| IL-11 Concentration (mg/mL) | 50 mM sodium phosphate, 150 mM NaCl, pH 7.0 | 20 mM L-histidine, 300 mM glycine, pH 7.0 |
| 0.1 | 88.5° C | >96.0° C |
| 0.5 | 80.0° C | >96.0° C |
| 1.0 | 75.0° C | >96.0° C |
| 2.5 | 70.0° C | 95.0° C |
| 5.0 | 66.0° C | 94.0° C |

EXAMPLE 4 LONG-TERM IL-11 STABILITY

[0025] To assess longer term effects of glycine on IL-11 stability, IL-11 is incubated for up to 12 months, at different temperatures, in the presence of 10 mM sodium phosphate containing either 150 mM or 300 mM glycine. The data clearly demonstrate that the addition of more glycine aids in increasing the shelf-life stability of this protein in the liquid state, at elevated temperatures. Further, the absence of glycine altogether leads to a dramatic loss of rhIL-11 at elevated temperatures.

[0026] rhIL-11 is prepared, at 5.0 mg/mL in two formulations: 10 mM sodium phosphate, 300 mM glycine, pH 7.0 and 10 mM sodium phosphate, 150 mM glycine, pH 7.0. One mL samples are prepared in 2-mL molded vials (Kimble), stoppered and crimped, and incubated at six temperatures for up to 12 months (-80°C, -20°C, 2-8°C, 30°C, 40°C, 50°C). Protein recoveries are determined using a reversed-phase HPLC method and the results are shown in Table III.

Table III

| Effect of Glycine Concentration on Percent rhIL-11 Recoveries at Different Temperature | | |
|--|---|---|
| INCUBATION TEMPERATURE | 10 mM sodium phosphate 300 mM glycine, pH 7.0 | 10 mM sodium phosphate 150 mM glycine, pH 7.0 |
| -80° C at 12 months | 100 | 100 |
| -20° C at 12 months | 96.9 | 97.2 |
| 2-8° C at 12 months | 98.3 | 100 |
| 30° C at 12 months | 91.5 | 71.7 |
| 40° C at 6 months | 72.4 | 63.2 |
| 50° C at 2 months | 72.9 | 75.5 |

[0027] Another set of samples is prepared in a formulation of 10 mM sodium phosphate, 300 mM glycine, pH 7.0. These samples are liquid and stored at 2-8°C for up to 18 months. The samples retain IL-11 activity.

[0028] Another set of samples is prepared in a formulation of 20 mM L-histidine, 300 mM glycine, pH 7.0. These samples are lyophilized and stored at 2-8°C for up to 18 months. The samples retain IL-11 activity.

[0029] While the present invention has been described in terms of specific methods and compositions, it is understood

that variations and modifications will occur to those skilled in the art upon consideration of the present invention.
[0030] Numerous modifications and variations in the invention as described in the above illustrative examples are expected to occur to those skilled in the art and, consequently, only such limitations as appear in the appended claims should be placed thereon. Accordingly, it is intended in the appended claims to cover all such equivalent variations which come within the scope of the invention as claimed.

Claims

1. A composition comprising IL-11 and glycine and a buffering agent.
2. The composition of claim 1, where said buffering agent is a member selected from the group consisting of histidine and phosphate.
3. The composition of claim 2, where said buffering agent is sodium phosphate.
4. The composition of any one of claims 1 to 3, where said glycine ranges from 50 to 600 mM.
5. The composition of claim 4, where said glycine is about 300 mM.
6. The composition of claim 4, where said glycine is about 150 mM.
7. The composition of any one of claims 1 to 6, where said IL-11 is about 0.1 to 20 mg/mL.
8. The composition of claim 7, where said IL-11 is about 5.0 mg/mL.
9. The composition of any one of claims 2 to 8, where said phosphate ranges from about 5 mM to 20 mM.
10. The composition of claim 9, where said phosphate is about 10 mM.
11. The composition of any one of claims 2 to 10, where said histidine ranges from about 5 mM to 40 mM.
12. The composition of claim 11, where said histidine is about 20 mM.
13. The composition of any one of claims 1 to 5 and 7 to 12, comprising about 5.0 mg/mL IL-11, 300 mM glycine, and 10 mM sodium phosphate.
14. The composition of any one of claims 1 to 5 and 7 to 12, comprising about 5.0 mg/mL IL-11, 300 mM glycine, and 20 mM histidine.

Patentansprüche

1. Zusammensetzung enthaltend IL-11, Glycin und ein Puffermittel.
2. Zusammensetzung nach Anspruch 1, wobei das Puffermittel ausgewählt ist aus der Gruppe bestehend aus Histidin und Phosphat.
3. Zusammensetzung nach Anspruch 2, wobei das Puffermittel Natriumphosphat ist.
4. Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei die Menge an Glycin zwischen 50 und 600 mM liegt.
5. Zusammensetzung nach Anspruch 4, wobei die Menge an Glycin etwa 300 mM beträgt.
6. Zusammensetzung nach Anspruch 4, wobei die Menge an Glycin etwa 150 mM beträgt.
7. Zusammensetzung nach einem der Ansprüche 1 bis 6, wobei die Menge an IL-11 etwa 0,1 bis 20 mg/ml beträgt.

8. Zusammensetzung nach Anspruch 7, wobei die Menge und IL-11 etwa 5,0 mg/ml beträgt.
9. Zusammensetzung nach einem der Ansprüche 2 bis 8, wobei die Menge an Phosphat im Bereich von etwa 5 mM bis 20 mM liegt.
10. Zusammensetzung nach Anspruch 9, wobei die Menge an Phosphat etwa 10 mM beträgt.
11. Zusammensetzung nach einem der Ansprüche 2 bis 10, wobei die Menge an Histidin im Bereich von etwa 5 mM bis 40 mM liegt.
12. Zusammensetzung nach Anspruch 11, wobei die Menge an Histidin etwa 20 mM beträgt.
13. Zusammensetzung nach einem der Ansprüche 1 bis 5 und 7 bis 12 umfassend etwa 5,0 mg/ml IL-11, 300 mM Glycin und 10 mM Natriumphosphat.
14. Zusammensetzung nach einem der Ansprüche 1 bis 5 und 7 bis 12 umfassend etwa 5,0 mg/ml IL-11, 300 mM Glycin und 20 mM Histidin.

Revendications

1. Composition comprenant de l'IL-11 et de la glycine et un agent tampon.
2. Composition selon la revendication 1, dans laquelle ledit agent tampon est choisi parmi le groupe constitué par l'histidine et le phosphate.
3. Composition selon la revendication 2, dans laquelle ledit agent tampon est le phosphate de sodium.
4. Composition selon l'une quelconque des revendications 1 à 3, dans laquelle ladite glycine est à une concentration comprise entre 50 et 600 mM.
5. Composition selon la revendication 4, dans laquelle ladite glycine est à une concentration d'environ 300 mM.
6. Composition selon la revendication 4, dans laquelle ladite glycine est à une concentration d'environ 150 mM.
7. Composition selon l'une quelconque des revendications 1 à 6, dans laquelle ladite IL-11 a une teneur d'environ 0,1 à 20 mg/ml.
8. Composition selon la revendication 7, dans laquelle ladite IL-11 a une teneur d'environ 5,0 mg/ml.
9. Composition selon l'une quelconque des revendications 2 à 8, dans laquelle ledit phosphate est à une concentration d'environ 5 mM à 20 mM.
10. Composition selon la revendication 9, dans laquelle ledit phosphate est à une concentration d'environ 10 mM.
11. Composition selon l'une quelconque des revendications 2 à 10, dans laquelle ladite histidine est à une concentration d'environ 5 mM à 40 mM.
12. Composition selon la revendication 11, dans laquelle ladite histidine est à une concentration d'environ 20 mM.
13. Composition selon l'une quelconque des revendications 1 à 5 et 7 à 12, ayant une teneur d'environ 5,0 mg/ml d'IL-11 et une concentration de glycine à 300 mM et de phosphate de sodium à 10 mM.
14. Composition selon l'une quelconque des revendications 1 à 5 et 7 à 12 ayant une teneur d'environ 5,0 mg/ml d'IL-11 et une concentration de glycine à 300 mM et d'histidine à 20 mM.